Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Gastric cancer (GC) is the fifth most common cancer worldwide and is a poor prognosis disease. GC is diagnosed by endoscopic biopsy and staged with CT scan, endoscopic ultrasound, and laparoscopy. An MDT approach is of major importance to plan a tailored-made treatment for GC patients. Very early GCs are treated with endoscopic resection, while locally advanced GCs are treated with radical surgery accompanied by perioperative chemotherapy or adjuvant chemotherapy or chemoradiotherapy when appropriate. The management of advanced GCs is based on sequential lines of systemic treatments that include combination of chemotherapies, targeted therapies, or immunotherapies. The possible benefit of local treatments in advanced disease still needs to be clarified.

Original publication

DOI

10.1016/B978-0-443-15609-0.00017-9

Type

Chapter

Book title

Medical Oncology Compendium

Publication Date

01/01/2025

Pages

245 - 268